The DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
Open accessAbstract
Assessment of Alzheimer's disease (AD)-related neurofibrillary pathology requires a procedure that permits a sufficient differentiation between initial, intermediate, and late stages. The gradual deposition of a hyperphosphorylated tau protein within select neuronal types in specific nuclei or areas is central to the disease process. The staging of AD-related neurofibrillary pathology originally described in 1991 was performed on unconventionally thick sections (100 mum) using a modern silver technique and reflected the progress of the disease process based chiefly on the topographic expansion of the lesions. To better meet the demands of routine laboratories this procedure is revised here by adapting tissue selection and processing to the needs of paraffin-embedded sections (5-15 mum) and by introducing a robust immunoreaction (AT8) for hyperphosphorylated tau protein that can be processed on an automated basis. It is anticipated that this revised methodological protocol will enable a more uniform application of the staging procedure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accumulation of Aβ plaques and NFTs follows distinct regional progressions across brain regions as AD advances.”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with the stereotypical hierarchical accumulation of NFTs along neural networks20,21”
From Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer’s disease (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They were categorized into the stage C of amyloid deposition and the stage VI of neurofibrillary degeneration, following the Braak's staging (13).”
From Microglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease (2017) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“by definition, the primary visual cortex (V1 region) bears NFTs only in Braak NFT stage VI20,21”
From Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer’s disease (2024) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“we rank ordered the five brain regions based on their known vulnerability to neurofibrillary degeneration20,21 (that is, EC > ITG > PFC > V2 > V1)”
From Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer’s disease (2024) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“the distinguishing feature between Braak NFT stages V and VI is not just the presence of NFTs in the primary visual (V1), motor and sensory cortical areas, but more severe neurofibrillary degeneration21 and atrophy throughout the cortical mantle51”
From Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer’s disease (2024) · cites this paper as [21]
In the citing paper
“A further pathological determinant is loss of neurons, which occurs predominantly in the cortex, the hippocampal formation, and the nucleus basalis of Meynert [2, 3, 18, 22, 25].”
From Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice (2008) · cites this paper as [2]
In the citing paper
“We consider it to be an important clue that most brains from elderly human subjects show abnormalities that fall somewhere along particular continua of pathologic severity (60, 96-100).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Self-citationNeurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Self-citationFrequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Self-citationHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
(1964) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1964.tb115841.x · Cited by 1,411
Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., & Van Hoesen, G. W. (1991) · Cerebral Cortex · doi:10.1093/cercor/1.1.103 · Cited by 1,380
The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease.
Delacourte, A., David, J. P., Sergeant, N., Buée, L., Wattez, A., Vermersch, P., Ghozali, F., Fallet-Bianco, C., Pasquier, F., Lebert, F., et al. (1999) · Neurology · doi:10.1212/wnl.52.6.1158 · Cited by 828
Bancher, C., Brunner, C., Lassmann, H., Budka, H., Jellinger, K., Wiche, G., Seitelberger, F., Grundke-Iqbal, I., Iqbal, K., & Wisniewski, H. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)91396-6 · Cited by 818
Braak, F., Braak, H., & Mandelkow, E. (1994) · Acta Neuropathologica · doi:10.1007/bf00293315 · Cited by 769
Self-citation
Research works printed but not linked: 7
- Alzheimer A (1906) Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurolog Centralbl 23:1129–1136
- Bielschowsky M (1902) Die Silberimprägnation der Axenzylinder. Neurol Centralb 13:579–584
- Bielschowsky M (1903) Die Silberimprägnation der Neurofibrillen. Neurol Centralb 21:997–1006
- Bielschowsky M (1904) Die Silberimprägnation der Neurofibrillen. Einige Bemerkungen zu der von mir angegebenen Methode und den von ihr gelieferten Bildern. J Psychol Neurol 3:169–189
- Bielschowsky M (1905) Die Darstellung der Axenzylinder peripherischer Nervenfasern und der Axenzylinder zentraler markhaltiger Nervenfasern. Ein Nachtrag zu der von mir angegebenen Imprägnationsmethode der Neurofibrillen. J Psychol Neurol 4:228–231
- Bielschowsky M (1909) Eine Modifikation meines Silberimprägnations-verfahrens zur Darstellung der Neurofibrillen. J Psychol Neurol 12:135–137
- Duyckaerts C, He Y, Seilhean D, Delaère P, Piette F, Braak H, Hauw JJ (1994) Diagnosis and staging of Alzheimer’s disease in a prospective study involving aged individuals. Neurobiol Aging 15(Suppl 1):140–141
Cited by
Sorted by citations
Items 401–500 of 1,028
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Frosch, M. P., Betensky, R. A., & Hyman, B. T. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000016 · Cited by 106
Rhodius‐Meester, H. F. M., Benedictus, M. R., Wattjes, M. P., Barkhof, F., Scheltens, P., Muller, M., & van der Flier, W. M. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00117 · Cited by 108
Vascular Risk and β ‐Amyloid Are Synergistically Associated with Cortical Tau
Rabin, J. S., Yang, H., Schultz, A. P., Hanseeuw, B. J., Hedden, T., Viswanathan, A., Gatchel, J. R., Marshall, G. A., Kilpatrick, E. P., Klein, H., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25399 · Cited by 110
Repetitive negative thinking is associated with amyloid, tau, and cognitive decline
Marchant, N. L., Lovland, L. R., Jones, R., Binette, A. P., Gonneaud, J., Arenaza‐Urquijo, E. M., Chételat, G., & Villeneuve, S. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12116 · Cited by 115
Matušková, V., Ismail, Z., Nikolai, T., Marková, H., Čechová, K., Nedelská, Z., Laczó, J., Wang, M., Hort, J., & Vyhnálek, M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.643271 · Cited by 109
Brenowitz, W. D., Monsell, S. E., Schmitt, F. A., Kukull, W. A., & Nelson, P. T. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131880 · Cited by 108
Lavretsky, H., Siddarth, P., Kepe, V., Ercoli, L. M., Miller, K. J., Burggren, A. C., Bookheimer, S. Y., Huang, S., Barrio, J. R., & Small, G. W. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181953b82 · Cited by 108
Lohith, T. G., Bennacef, I., Vandenberghe, R., Vandenbulcke, M., Salinas, C. A., Declercq, R., Reynders, T., Telan-Choing, N. F., Riffel, K., Celen, S., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.208215 · Cited by 107
Ivashko-Pachima, Y., Hadar, A., Grigg, I., Korenková, V., Kapitansky, O., Karmon, G., Gershovits, M., Sayas, C. L., Kooy, R. F., Attems, J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0563-5 · Cited by 107
Fišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 113
Alzheimer's disease-related amyloid-β induces synaptotoxicity in human iPS cell-derived neurons
Nieweg, K., Andreyeva, A., van Stegen, B., Tanriöver, G., & Gottmann, K. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.72 · Cited by 105
Besser, L. M., Teylan, M., & Nelson, P. T. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz126 · Cited by 109
Tomé, S. O., Vandenberghe, R. R., Ospitalieri, S., Schoor, E. V., Tousseyn, T., Otto, M., Arnim, C. A. F. V., & Thal, D. R. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00934-5 · Cited by 105
Circular RNA Cwc27 contributes to Alzheimer’s disease pathogenesis by repressing Pur-α activity
Song, C., Zhang, Y., Huang, W., Shi, J., Huang, Q., Jiang, M., Qiu, Y. L., Wang, T., Chen, H., & Wang, H. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00865-1 · Cited by 109
Lal, C., Ayappa, I. A., Ayas, N., Beaudin, A. E., Hoyos, C. M., Kushida, C. A., Kamińska, M., Mullins, A. E., Naismith, S. L., Osorio, R. S., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202205-380st · Cited by 114
Alzheimer's disease: Pathogenesis and prevention
Braak, H., & Tredici, K. D. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.01.011 · Cited by 110
Self-citationSerrano‐Pozo, A., Qian, J., Muzikansky, A., Monsell, S. E., Montine, T. J., Frosch, M. P., Betensky, R. A., & Hyman, B. T. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw026 · Cited by 110
Overlapping but distinct TDP‐43 and tau pathologic patterns in aged hippocampi
Smith, V. D., Bachstetter, A. D., Ighodaro, E. T., Roberts, K. N., Abner, E. L., Fardo, D. W., & Nelson, P. T. (2017) · Brain Pathology · doi:10.1111/bpa.12505 · Cited by 105
Fleitas, C., Piñol‐Ripoll, G., Marfull‐Oromí, P., Rocandio, D., Ferrer, I., Rampon, C., Egea, J., & Espinet, C. (2018) · Molecular Brain · doi:10.1186/s13041-018-0411-6 · Cited by 104
Deep learning detection of informative features in tau PET for Alzheimer’s disease classification
Jo, T., Nho, K. T., Risacher, S. L., Saykin, A. J., & Initiative, A. D. N. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03848-0 · Cited by 108
Salminen, A., Haapasalo, A., Kauppinen, A., Kaarniranta, K., Soininen, H. S., & Hiltunen, M. O. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.001 · Cited by 107
Amniai, L., Barbier, P., Sillen, A., Wieruszeski, J.-M., Peyrot, V., Lippens, G., & Landrieu, I. (2009) · The FASEB Journal · doi:10.1096/fj.08-121590 · Cited by 105
Microglial large extracellular vesicles propagate early synaptic dysfunction in Alzheimer’s disease
Gabrielli, M., Prada, I., Joshi, P., Falcicchia, C., D’Arrigo, G., Rutigliano, G., Battocchio, E., Zenatelli, R., Tozzi, F., Radeghieri, A., et al. (2022) · Brain · doi:10.1093/brain/awac083 · Cited by 106
Wong, D. F., Comley, R. A., Kuwabara, H., Rosenberg, P. B., Resnick, S. M., Ostrowitzki, S., Vozzi, C., Boess, F., Oh, E. S., Lyketsos, C. G., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.209916 · Cited by 105
Cheng, H., Wang, M., Li, J., Cairns, N. J., & Han, X. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12368 · Cited by 103
Crtc1 Activates a Transcriptional Program Deregulated at Early Alzheimer's Disease-Related Stages
Parra‐Damas, A., Valero, J., Chen, M., España, J., Martín, E., Ferrer, I., Rodrı́guez-Álvarez, J., & Saura, C. A. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.5288-13.2014 · Cited by 104
Schütt, T., Helboe, L., Pedersen, L. Ø., Waldemar, G., Berendt, M., & Pedersen, J. T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151085 · Cited by 105
Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease
Bischof, G. N., Jessen, F., Fließbach, K., Dronse, J., Hammes, J., Neumaier, B., Onur, O. A., Fink, G. R., Kukolja, J., Drzezga, A. E., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.339 · Cited by 104
Contribution of mixed pathology to medial temporal lobe atrophy in Alzheimer's disease
de Florès, R., Wisse, L. E. M., Das, S. R., Xie, L., McMillan, C. T., Trojanowski, J. Q., Robinson, J. L., Grossman, M., Lee, E. B., Irwin, D. J., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12079 · Cited by 103
Thal, D. R., Papassotiropoulos, A., Saido, T. C., Griffin, W. S. T., Mrak, R. E., Kölsch, H., Tredici, K. D., Attems, J., & Ghebremedhin, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0707-9 · Cited by 103
Self-citationβ‐Amyloid deposition in brains of subjects with diabetes
Alafuzoff, I. I., Aho, L., Helisalmi, S., Mannermaa, A., & Soininen, H. S. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.00948.x · Cited by 102
Self-citationIncreased number of heterotopic Purkinje cells in essential tremor
Kuo, S., Erickson-Davis, C. R., Gillman, A., Faust, P. L., Vonsattel, J., & Louis, E. D. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.213330 · Cited by 103
Prion-like Spreading in Tauopathies
Ayers, J. I., Giasson, B. I., & Borchelt, D. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.04.003 · Cited by 106
Hecht, M., Krämer, L. M., Arnim, C., Otto, M., & Thal, D. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1834-y · Cited by 92
Compta, Y., Parkkinen, L., Kempster, P. A., Selikhova, M., Lashley, T., Holton, J. L., Lees, A. J., & Révész, T. (2013) · Neurodegenerative Diseases · doi:10.1159/000354670 · Cited by 102
Simpson, J. E., Ince, P. G., Haynes, L. J., Theaker, R., Gelsthorpe, C., Baxter, L., Forster, G., Lace, G., Shaw, P. J., Matthews, F. E., et al. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2009.01030.x · Cited by 104
Vitali, P., Migliaccio, R., Agosta, F., Rosen, H., & Geschwind, M. D. (2008) · Seminars in Neurology · doi:10.1055/s-0028-1083695 · Cited by 105
Leinonen, V., Koivisto, A. M., Savolainen, S., Rummukainen, J., Sutela, A., Vanninen, R. L., Jääskeläinen, J. E., Soininen, H. S., & Alafuzoff, I. I. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01195.x · Cited by 101
Self-citationCharacteristics of Tau and Its Ligands in PET Imaging
Harada, R., Okamura, N., Furumoto, S., Tago, T., Yanai, K., Arai, H., & Kudo, Y. (2016) · Biomolecules · doi:10.3390/biom6010007 · Cited by 104
Sun, M., Bell, W., LaClair, K. D., Ling, J. P., Han, H., Kageyama, Y., Pletniková, O., Troncoso, J. C., Wong, P. C., & Chen, L. L. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1701-2 · Cited by 106
Mano, T., Nagata, K., Nonaka, T., Tarutani, A., Imamura, T., Hashimoto, T., Bannai, T., Mano, K. K., Tsuchida, T., Ohtomo, R., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707151114 · Cited by 105
Ercan-Herbst, E., Ehrig, J., Schöndorf, D. C., Behrendt, A., Klaus, B., Gomez Ramos, B., Prat Oriol, N., Weber, C., & Ehrnhoefer, D. E. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0823-2 · Cited by 101
Torpedoes in Parkinson's disease, Alzheimer's disease, essential tremor, and control brains
Louis, E. D., Faust, P. L., Vonsattel, J., Honig, L. S., Rajput, A. H., Rajput, A. H., Pahwa, R., Lyons, K. E., Ross, W. G., Elble, R. J., et al. (2009) · Movement Disorders · doi:10.1002/mds.22567 · Cited by 101
The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease
Jembrek, M. J., Slade, N., Hof, P. R., & Šimić, G. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.05.001 · Cited by 101
Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities
Visanji, N. P., Lang, A. E., & Kovács, G. G. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0172-x · Cited by 102
Thal, D. R., Attems, J., & Ewers, M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141461 · Cited by 100
Rates of Decline in Alzheimer Disease Decrease with Age
Holland, D., Desikan, R. S., Dale, A. M., McEvoy, L. K., & Initiative, A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042325 · Cited by 104
Lachén‐Montes, M., González-Morales, A., Zelaya, M. V., Pérez‐Valderrama, E., Ausín, K., Ferrer, I., Fernández‐Irigoyen, J., & Santamaría, E. (2017) · Scientific Reports · doi:10.1038/s41598-017-09481-x · Cited by 97
Whitesell, J. D., Buckley, A. R., Knox, J. E., Kuan, L., Graddis, N., Pelos, A., Mukora, A., Wakeman, W., Bohn, P., Ho, A., et al. (2019) · Journal of Comparative Neurology · doi:10.1002/cne.24555 · Cited by 99
Alzheimer’s disease: A clinical perspective and future nonhuman primate research opportunities
Haque, R. U., & Levey, A. I. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912954116 · Cited by 99
McAleese, K. E., Miah, M., Graham, S., Hadfield, G. M., Walker, L., Johnson, M. A., Colloby, S. J., Thomas, A. J., DeCarli, C. S., Koss, D. J., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02376-2 · Cited by 95
Celarain, N., de Gordoa, J. S., Zelaya, M. V., Roldán, M., Larumbe, R., Pulido, L., Echávarri, C., & Mendióroz, M. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0202-9 · Cited by 103
Kobayashi, E., Nakano, M., Kubota, K., Himuro, N., Mizoguchi, S., Chikenji, T., Otani, M., Mizue, Y., Nagaishi, K., & Fujimiya, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-19442-7 · Cited by 98
Current Concepts of Mixed Pathologies in Neurodegenerative Diseases
Forrest, S. L., & Kovács, G. G. (2022) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2022.34 · Cited by 104
Węgiel, J., Kaczmarski, W., Barua, M., Kuchna, I., Nowicki, K., Wang, K.-C., Wegiel, J., Mazur‐Kolecka, B., Frackowiak, J., Mazur‐Kolecka, B., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318202bfa1 · Cited by 98
Erickson, M. A., Hansen, K. M., & Banks, W. A. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.07.003 · Cited by 102
Human High Temperature Requirement Serine Protease A1 (HTRA1) Degrades Tau Protein Aggregates
Tennstaedt, A., Poepsel, S., Truebestein, L., Hauske, P., Brockmann, A., Schmidt, N., Irle, I., Saccà, B., Niemeyer, C. M., Brandt, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.316232 · Cited by 104
Giannakopoulos, P., Gold, G., Kövari, E., von Gunten, A., Imhof, A., Bouras, C., & Hof, P. R. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0144-y · Cited by 96
Baker, S., Polanco, J. C., & Götz, J. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160371 · Cited by 98
Characterization of tau prion seeding activity and strains from formaldehyde-fixed tissue
Kaufman, S. K., Thomas, T. L., Tredici, K. D., Braak, H., & Diamond, M. I. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0442-8 · Cited by 97
Self-citationLatimer, C. S., Burke, B. T., Liachko, N. F., Currey, H. N., Kilgore, M. D., Gibbons, L. E., Henriksen, J. C., Darvas, M., Domoto‐Reilly, K., Jayadev, S., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0743-1 · Cited by 102
Whittington, R. A., Bretteville, A., Dickler, M., & Planel, E. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.03.004 · Cited by 101
Cassidy, C., Therriault, J., Pascoal, T. A., Cheung, V., Savard, M., Tuominen, L. J., Chamoun, M., McCall, A., Celebi, S., Lussier, F. Z., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01293-6 · Cited by 99
Antonell, A., Lladó, A., Altirriba, J., Botta‐Orfila, T., Balasa, M., Fernández, M., Ferrer, I., Sánchez‐Valle, R., & Molinuevo, J. L. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.026 · Cited by 101
Viggars, A. P., Wharton, S. B., Simpson, J. E., Matthews, F. E., Brayne, C., Savva, G. M., Garwood, C. J., Drew, D., Shaw, P. J., & Ince, P. G. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.09.049 · Cited by 96
Hansson, O., Grothe, M. J., Strandberg, T. O., Ohlsson, T. G., Hägerström, D., Jögi, J., Smith, R. A., & Schöll, M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00167 · Cited by 102
The coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer’s disease
Boon, B. D. C., Bulk, M., Jonker, A. J., Morrema, T. H. J., van den Berg, E., Popovic, M. M., Walter, J., Kumar, S., van der Lee, S. J., Holstege, H. H., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02198-8 · Cited by 99
The Effects of NOS2 Gene Deletion on Mice Expressing Mutated Human AβPP
Colton, C. A., Wilcock, D. M., Wink, D. A., Davis, J., Nostrand, W. E. V., & Vitek, M. P. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15405 · Cited by 92
Wilcock, D. M., Gharkholonarehe, N., Nostrand, W. E. V., Davis, J., Vitek, M. P., & Colton, C. A. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1339-09.2009 · Cited by 98
Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study
Cho, H., Choi, J. Y., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., Jack, C. R., & Lyoo, C. H. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.221697 · Cited by 94
Lockhart, S. N., Baker, S. L., Okamura, N., Furukawa, K., Ishiki, A., Furumoto, S., Tashiro, M., Yanai, K., Arai, H., Kudo, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158460 · Cited by 100
Region-specific vulnerability in neurodegeneration: lessons from normal ageing
Pandya, V. A., & Patani, R. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101311 · Cited by 98
Estes, R., Lin, B. C., Khera, A., & Davis, M. Y. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.788695 · Cited by 99
Nguyen, T. V., Shen, L., Griend, L. V., Quach, L. N., Belichenko, N. P., Saw, N. L., Yang, T., Shamloo, M., Wyss‐Coray, T., Massa, S. M., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140036 · Cited by 93
Selective alterations of neurons and circuits related to early memory loss in Alzheimer’s disease
Llorens-Martı́n, M., Blázquez‐Llorca, L., Benavides‐Piccione, R., Rábano, A., Hernández, F., Ávila, J., & DeFelipe, J. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00038 · Cited by 94
Prions and Protein Assemblies that Convey Biological Information in Health and Disease
Sanders, D. W., Kaufman, S. K., Holmes, B. B., & Diamond, M. I. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.026 · Cited by 92
Shcherbinin, S., Schwarz, A. J., Joshi, A. D., Navitsky, M. A., Flitter, M. L., Shankle, W. R., Devous, M. D., & Mintun, M. A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.170027 · Cited by 93
Hyperphosphorylation Renders Tau Prone to Aggregate and to Cause Cell Death
Liu, M., Sui, D., Dexheimer, T. S., Hovde, S., Deng, X., Wang, K., Lin, H. L., Hagar, H. C., Kweon, H. K., Kuo, N. S., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02034-w · Cited by 98
Cerebrovascular disease promotes tau pathology in Alzheimer’s disease
Laing, K. K., Simoes, S., Baena-Caldas, G. P., Lao, P. J., Kothiya, M., Igwe, K. C., Chesebro, A. G., Houck, A. L., Pedraza, L., Hernandez, A. I., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa132 · Cited by 94
Whiteman, I. T., Gervasio, O. L., Cullen, K. M., Guillemin, G. J., Jeong, E. V., Witting, P. K., Antao, S. T., Minamide, L. S., Bamburg, J. R., & Goldsbury, C. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3531-09.2009 · Cited by 92
Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer’s disease pathology
Rosenberger, A. F. N., Morrema, T. H. J., Gerritsen, W. H., van Haastert, E. S., Snkhchyan, H., Hilhorst, R., Rozemüller, A. J. M., Scheltens, P., van der Vies, S. M., & Hoozemans, J. J. M. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0470-x · Cited by 99
Dementia After Moderate-Severe Traumatic Brain Injury: Coexistence of Multiple Proteinopathies
Kenney, K., Iacono, D., Edlow, B. L., Katz, D. I., Diaz-Arrastia, R. R., Dams-O’Connor, K., Daneshvar, D. H., Stevens, A. A., Moreau, A. L., Tirrell, L. S., et al. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx101 · Cited by 91
Alonso‐Andrés, P., Albasanz, J. L., Ferrer, I., & Martı́n, M. (2018) · Brain Pathology · doi:10.1111/bpa.12592 · Cited by 96
Multimodal mapping and analysis of the cyto- and receptorarchitecture of the human hippocampus
Palomero‐Gallagher, N., Kedo, O., Mohlberg, H., Zilles, K., & Amunts, K. (2020) · Brain Structure and Function · doi:10.1007/s00429-019-02022-4 · Cited by 90
Kim, B.-K., Shin, M., Kim, C., Baek, S.-B., Ko, Y.-C., & Kim, Y.-P. (2014) · Journal of Exercise Rehabilitation · doi:10.12965/jer.140086 · Cited by 92
Neuroimaging and APOE Genotype: A Systematic Qualitative Review
Cherbuin, N., Leach, L., Christensen, H. M., & Anstey, K. J. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000109150 · Cited by 93
Ling, H., de Silva, R., Massey, L. A., Courtney, R. J., Hondhamuni, G., Bajaj, N. P. S., Lowe, J. S., Holton, J. L., Lees, A. J., & Révész, T. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12037 · Cited by 97
Pijnenburg, Y. A. L., Verwey, N. A., van der Flier, W. M., Scheltens, P., & Teunissen, C. E. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.11.001 · Cited by 91
Purkinje cell loss in essential tremor: Random sampling quantification and nearest neighbor analysis
Choe, M., Cortes, E. P., Vonsattel, J., Kuo, S., Faust, P. L., & Louis, E. D. (2016) · Movement Disorders · doi:10.1002/mds.26490 · Cited by 91
SFPQ and Tau: critical factors contributing to rapid progression of Alzheimer’s disease
Younas, N., Zafar, S., Shafiq, M., Noor, A., Siegert, A., Arora, A. S., Galkin, A. P., Zafar, A., Schmitz, M., Stadelmann, C., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02178-y · Cited by 94
Close association of water channel AQP1 with amyloid-β deposition in Alzheimer disease brains
Misawa, T., Arima, K., Mizusawa, H., & Satoh, J. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0387-x · Cited by 90
Kovács, G. G., Andreasson, U., Liman, V., Regelsberger, G., Lutz, M. I., Danics, K., Keller, É., Zetterberg, H., & Blennow, K. (2017) · European Journal of Neurology · doi:10.1111/ene.13389 · Cited by 93
Franzmeier, N., Ren, J., Damm, A., Monté, G. C., Boada, M., Ruiz, A., Ramı́rez, A., Jessen, F., Düzel, E., Rodríguez‐Gómez, O., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0404-6 · Cited by 86
Tayler, H. M., Miners, J. S., Güzel, Ö., MacLachlan, R. A., & Love, S. (2021) · Brain Pathology · doi:10.1111/bpa.12935 · Cited by 90
Kerchner, G. A., & Boxer, A. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.493872 · Cited by 92
A peculiar constellation of tau pathology defines a subset of dementia in the elderly
Kovács, G. G., Molnár, K., László, L., Ströbel, T., Botond, G., Hönigschnabl, S., Reiner‐Concin, A., Palkovits, M., Fischer, P. A., & Budka, H. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0819-x · Cited by 90
Manousopoulou, A., Gatherer, M., Smith, C., Nicoll, J. A. R., Woelk, C. H., Johnson, M., Kalaria, R. N., Attems, J., Garbis, S. D., & Carare, R. O. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12342 · Cited by 90
Climbing fiber-Purkinje cell synaptic pathology in tremor and cerebellar degenerative diseases
Kuo, S., Lin, C.-Y. R., Wang, J., Sims, P. A., Pan, M., Liou, J.-Y., Lee, D., Tate, W. J., Kelly, G. C., Louis, E. D., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1626-1 · Cited by 89
Sala, A., & Perani, D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00617 · Cited by 88
Monsell, S. E., Kukull, W. A., Roher, A. E., Maarouf, C. L., Serrano, G., Beach, T. G., Caselli, R. J., Montine, T. J., & Reiman, E. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1721 · Cited by 82
Metadata
- Authors
- Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K.
- Affiliations
- Goethe University Frankfurt (DE)
- Kuopio University Hospital (FI)
- Institut für Neuropathologie (DE)
- Corresponding author
- Braak, Heiko
- Venue
- Acta Neuropathologica
- Published
- 2006-08-12
- Volume
- 112
- Issue
- 4
- Pages
- 389-404
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC3906709
- OpenAlex
- W2093650784
- Cited by
- 3,172
- References
- 101
- Citations by year
- 2026: 218 · 2025: 259 · 2024: 334 · 2023: 254 · 2022: 251 · 2021: 261 · 2020: 228 · 2019: 205 · 2018: 157 · 2017: 135 · 2016: 140 · 2015: 118 · 2014: 134 · 2013: 95 · 2012: 77
- FWCI
- 34.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Acta Neuropathologica (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission (LSHM-CT-2004-503039)
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, neurofibrillary pathology, disease staging, AT8 antibody, immunocytochemistry, paraffin sections, silver staining
- MeSH terms
- Alzheimer Disease, Humans, Immunohistochemistry, Amyloid beta-Peptides, Paraffin Embedding, Tissue Fixation, Neurofibrillary Tangles, tau Proteins, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
